Valesco Industries, headquartered in Dallas, has successfully concluded the divestiture of its stake in Drug Free Sport International, passing it on to CPC LLC, an investment firm located in Kansas City, Missouri.
The specifics regarding the financial aspects of the deal have been kept private. Valesco made its initial majority investment in DFSI in January 2017. Following this, DFSI joined forces with IDTM from Stockholm, Sweden, in a merger that took place in September 2018.
DFSI, operating out of Kansas City, serves as a global independent authority that administers comprehensive anti-doping education and testing programs tailored for both professional and amateur sports leagues, in addition to offering clinical and mobile health services as an external provider.
Chris Guinty, the CEO of DFSI, expressed gratitude towards Valesco Industries for its significant role in streamlining vital operational aspects, broadening the company’s service offerings, and facilitating its growth by providing essential resources to strengthen its market presence. Guinty highlighted Valesco’s partnership approach, emphasizing their focus on the company’s long-term success and heritage over mere financial gains.
During Valesco’s tenure as an investor, the firm achieved significant milestones in enhancing human resources, operational processes, and system integration, which, in turn, led to an unprecedented increase in sales and EBITDA. CPC’s investment strategy, as detailed on its website, involves making control investments ranging from $60 million to $120 million or more in each company.
Boxwood Partners acted as the sole financial advisor to both Drug Free Sport and Valesco Industries in this transaction.
